Strand Life Sciences’ CancerSpot shows promise in early detection of multiple cancers

/ 2 min read
AI Hub

The AI-powered genomic tool combines DNA sequencing with methylation analysis to distinguish cancer cells from normal cells, a four-year study across 43 hospitals finds.

Strand Life Sciences’ CancerSpot shows promise in detecting 14 types of cancer
Strand Life Sciences’ CancerSpot shows promise in detecting 14 types of cancer | Credits: Pexels

Bengaluru-based Strand Life Sciences has achieved a breakthrough in early cancer detection, with a four-year study demonstrating that its genomic technology tool, ‘CancerSpot’, can distinguish cancer cells from normal cells.

ADVERTISEMENT

The findings of Strand’s research have been published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS), a top-tier, high-impact scientific journal.

CancerSpot combines DNA sequencing with AI to identify methylation patterns, or chemical modifications of DNA, that distinguish cancer cells from normal cells.

ADVERTISEMENT

The study, conducted over the past four years as part of the development and clinical validation of CancerSpot, involved 43 hospitals across India and examined the biological factors influencing the detection of cancer-associated signals in the blood.

Higher DNA levels improve cancer detection

Using blood samples from 1,480 subjects, the study found that even among patients at the same cancer stage, higher levels of circulating DNA were associated with stronger cancer-related signals and greater cancer detection sensitivity. In other words, the contributions of tumour and immune cells to circulating DNA appear to rise in synchrony in cancer patients.

The study included newly diagnosed patients with 14 types of cancer, as well as healthy individuals. In an independent validation cohort, CancerSpot demonstrated a very low false-positive rate of just 1.4% and detected 72% of patients with cancer.

The review of the data by an international panel of experts lends confidence to the rigour and accuracy of the CancerSpot methodology, supporting its potential for early detection.

Recommended Stories

"In early cancer detection, clinical utility depends on walking a tightrope: maximizing sensitivity to catch disease early while minimizing false-positives that lead to unnecessary invasive procedures and patient harm. Achieving that balance requires deep scientific insight and rigorous validation. Having our work published in PNAS attests to the rigor of our science and the quality of our clinical evidence, marking a pivotal milestone in our mission to bring reliable, scalable early detection beyond the current standard-of-care, to India,” said Dr Ramesh Hariharan, CEO, Strand Life Sciences.

Cells in the body release short DNA fragments into the bloodstream. A very small fraction of this circulating DNA is contributed by tumour cells, if a tumour is present. CancerSpot looks for this DNA to detect the presence of cancer.

ADVERTISEMENT

Interestingly, in cancer patients, the amount of DNA originating from immune cells also rises substantially. This would be expected to dilute the tumour contribution and hamper cancer detection. However, the study shows the opposite.

“This research marks an important milestone for India’s contribution to global cancer research in precision-based early cancer detection. By showing that higher circulating cell-free DNA concentrations enrich, rather than dilute, cancer-associated methylation signals, this study challenges a fundamental assumption in liquid biopsy science and opens new possibilities for multicancer early detection. The priority now is to translate this discovery into independently validated screening strategies that improve early diagnosis and patient outcomes,” said Dr Sewanti Limaye, Director of Medical & Precision Oncology at Sir H.N. Reliance Foundation Hospital and a co-author of the study.

Follow Fortune India
NEXT STORY